Literature DB >> 34747413

Which bacterial toxins are worthy of validation as markers in colorectal cancer screening? A critical review.

Kristyna Mezerova1, Vladislav Raclavsky1, Lubomir Stary2.   

Abstract

Appropriate screening of early asymptomatic cases can reduce the disease burden and mortality rate of sporadic colorectal cancer (CRC) significantly. Currently, fecal occult blood testing (FOBT) is able to detect up to 80% of asymptomatic cases in the population aged 50+. Therefore, there is still a demand for new screening tests that would complement FOBT, mainly by detecting at least a part of the FOBT-negative CRC and adenoma cases, or possibly by identifying person at increased risk of sporadic CRC in order to offer them tailored follow-up. Among the potential markers studied, our knowledge has advanced at most in toxigenic gram-negative bacteria. In this review, we assess their potential critically and recommend those best suited for prospective evaluation of their true ability to increase the sensitivity of FOBT when combined during general population screening. In our opinion, colibactin and Bacteroides fragilis toxin are the best candidates, possibly complemented by the cytotoxic necrotizing factor (CNF).

Entities:  

Keywords:  Bacteroides fragilis toxin; colibactin; colorectal cancer; cycle inhibiting factor; cytolethal distending toxin; cytotoxic necrotizing factor; enterotixin

Mesh:

Substances:

Year:  2021        PMID: 34747413     DOI: 10.5507/bp.2021.054

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  90 in total

1.  Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells.

Authors:  Gabriel Cuevas-Ramos; Claude R Petit; Ingrid Marcq; Michèle Boury; Eric Oswald; Jean-Philippe Nougayrède
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  Use of epidemiological analyses in development of colorectal cancer clinical practice guidelines in the Czech Republic.

Authors:  Jitka Klugarová; Miloslav Klugar; Jan Mužík; Jiří Jarkovský; Radim Líčeník; Petra Búřilová; Dana Dolanová; Martin Hunčovský; Ladislav Dušek; Ivana Svobodová; Denisa Krejčí; Andrea Pokorná
Journal:  Int J Evid Based Healthc       Date:  2019-06

3.  [Population colorectal cancer screening in the Czech Republic].

Authors:  Miroslav Zavoral; Gabriela Vojtěchová; Ondřej Májek; Ondřej Ngo; Tomáš Grega; Bohumil Seifert; Ladislav Dušek; Štěpán Suchánek
Journal:  Cas Lek Cesk       Date:  2016

4.  Structure elucidation of colibactin and its DNA cross-links.

Authors:  Mengzhao Xue; Chung Sub Kim; Alan R Healy; Kevin M Wernke; Zhixun Wang; Madeline C Frischling; Emilee E Shine; Weiwei Wang; Seth B Herzon; Jason M Crawford
Journal:  Science       Date:  2019-08-08       Impact factor: 47.728

5.  Escherichia coli induces DNA double-strand breaks in eukaryotic cells.

Authors:  Jean-Philippe Nougayrède; Stefan Homburg; Frédéric Taieb; Michèle Boury; Elzbieta Brzuszkiewicz; Gerhard Gottschalk; Carmen Buchrieser; Jörg Hacker; Ulrich Dobrindt; Eric Oswald
Journal:  Science       Date:  2006-08-11       Impact factor: 47.728

6.  A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.

Authors:  Thibaut Raginel; Josette Puvinel; Olivier Ferrand; Veronique Bouvier; Romuald Levillain; Angela Ruiz; Olivier Lantieri; Guy Launoy; Lydia Guittet
Journal:  Gastroenterology       Date:  2013-02-01       Impact factor: 22.682

7.  Predictive power of quantitative and qualitative fecal immunochemical tests for hemoglobin in population screening for colorectal neoplasm.

Authors:  Yanqin Huang; Qilong Li; Weiting Ge; Shanrong Cai; Suzhan Zhang; Shu Zheng
Journal:  Eur J Cancer Prev       Date:  2014-01       Impact factor: 2.497

Review 8.  Colorectal cancer screening and diagnosis: omics-based technologies for development of a non-invasive blood-based method.

Authors:  María Gallardo-Gómez; Loretta De Chiara; Paula Álvarez-Chaver; Joaquin Cubiella
Journal:  Expert Rev Anticancer Ther       Date:  2021-02-10       Impact factor: 4.512

9.  Colibactin DNA-damage signature indicates mutational impact in colorectal cancer.

Authors:  Paulina J Dziubańska-Kusibab; Hilmar Berger; Federica Battistini; Britta A M Bouwman; Amina Iftekhar; Riku Katainen; Tatiana Cajuso; Nicola Crosetto; Modesto Orozco; Lauri A Aaltonen; Thomas F Meyer
Journal:  Nat Med       Date:  2020-06-01       Impact factor: 53.440

10.  Macrocyclic colibactin induces DNA double-strand breaks via copper-mediated oxidative cleavage.

Authors:  Zhong-Rui Li; Jie Li; Wenlong Cai; Jennifer Y H Lai; Shaun M K McKinnie; Wei-Peng Zhang; Bradley S Moore; Wenjun Zhang; Pei-Yuan Qian
Journal:  Nat Chem       Date:  2019-09-16       Impact factor: 24.427

View more
  2 in total

Review 1.  Emerging role of human microbiome in cancer development and response to therapy: special focus on intestinal microflora.

Authors:  Hourieh Sadrekarimi; Zhanna R Gardanova; Morteza Bakhshesh; Farnoosh Ebrahimzadeh; Amirhossein Fakhre Yaseri; Lakshmi Thangavelu; Zahra Hasanpoor; Firoozeh Abolhasani Zadeh; Mohammad Saeed Kahrizi
Journal:  J Transl Med       Date:  2022-07-06       Impact factor: 8.440

2.  Phenotypicand Genotypic Characterization of Clinical Isolates of Intracellular Adherent-Invasive Escherichia coli Among Different Stages, Family History, and Treated Colorectal Cancer Patients in Iran.

Authors:  Razie Kamali Dolatabadi; Hossein Fazeli; Mohammad Hassan Emami; Vajihe Karbasizade; Fatemeh Maghool; Alireza Fahim; Hojatollah Rahimi
Journal:  Front Cell Infect Microbiol       Date:  2022-07-11       Impact factor: 6.073

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.